<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548118</url>
  </required_header>
  <id_info>
    <org_study_id>311-HPV-1001</org_study_id>
    <nct_id>NCT01548118</nct_id>
  </id_info>
  <brief_title>Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females</brief_title>
  <official_title>A Blind, Randomized and Placebo-controlled Clinical Trial With Recombinant HumanPapillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Health Women-Phase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zerun Biotechnology Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zerun Biotechnology Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety of a novel recombinant human papillomavirus bivalent (
      types 16 and 18 ) vaccine ( Yeast ) with different dose in healthy females between 9-45 years
      of age at enrollment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of any solicited local or systemic reactions.</measure>
    <time_frame>7 days after each vaccine dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Occurrence, intensity and relationship to vaccination of any unsolicited symptom.</measure>
    <time_frame>30 days after finish vaccinations</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibody responses of HPV 16/18 after each vaccine dose.</measure>
    <time_frame>30 days after finish vaccinations</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">160</enrollment>
  <condition>Human Papillomavirus</condition>
  <arm_group>
    <arm_group_label>Adult Group 1, HPV vaccine 0.5ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Group 1, Placebo 0.5ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Group 2, HPV vaccine 1.0ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adult Group 2, Placebo 1.0ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 women between 18-45 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 1, HPV vaccine 0.5ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml experimental HPV vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 1, Placebo 0.5ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 0.5ml aluminum phosphate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 2, HPV vaccine 1.0ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml experimental HPV vaccines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Children Group 2, Placebo 1.0ml</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20 girls between 9-17 yeas of age, receiving 0,2,6 month-schedule of 1.0ml aluminum phosphate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV 16/18 vaccine, 0,5ml</intervention_name>
    <description>Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule</description>
    <arm_group_label>Adult Group 1, HPV vaccine 0.5ml</arm_group_label>
    <arm_group_label>Children Group 1, HPV vaccine 0.5ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo control, 0.5ml</intervention_name>
    <description>Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.</description>
    <arm_group_label>Adult Group 1, Placebo 0.5ml</arm_group_label>
    <arm_group_label>Children Group 1, Placebo 0.5ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HPV 16/18 vaccine, 1.0ml</intervention_name>
    <description>Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule</description>
    <arm_group_label>Adult Group 2, HPV vaccine 1.0ml</arm_group_label>
    <arm_group_label>Children Group 2, HPV vaccine 1.0ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo control, 1.0ml</intervention_name>
    <description>Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.</description>
    <arm_group_label>Adult Group 2, Placebo 1.0ml</arm_group_label>
    <arm_group_label>Children Group 2, Placebo 1.0ml</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female between, and including, 9 and 45 years of age at the time of the first
             vaccination

          -  Provide legal identification for for the sake of recruitment.

          -  Be able to understand and sign informed consent prior to enrollment (For subjects
             below the legal age of consent, informed consent must be signed by parent(s)/legal
             guardian(s) in addition).

          -  Subject must be not pregnant at the enrollment and agree to using adequate
             contraceptive precautions within 7 months.

        Exclusion Criteria:

          -  History of cervical cancer

          -  History of severe allergic reaction requiring medical intervention (such as oral and
             throat swelling, difficulty breathing, hypotension or shock)

          -  History of allergic to vaccine, or to any ingredient of vaccine.

          -  History of epilepsy, seizures or convulsions, or family history of mental illness

          -  Subjects are immunocompromised or have been diagnosed as suffering from congenital or
             acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus
             erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis inflammation
             (JRA), inflammatory bowel disease or other autoimmune diseases, administration of
             immunosuppressants with six months prior to the first vaccine dose.

          -  History of asthma, thyroidectomy, angioneurotic edema, diabetes or malignant

          -  Asplenia, functional asplenia, or any circumstances result of asplenia or splenectomy

          -  Medical diagnosis of coagulation abnormalities (eg, clotting factor deficiency,
             coagulation disorders, platelet anomaly) or obvious bruising or coagulation disorder

          -  Acute disease or chronic disease acute exacerbation 7 days prior to vaccination

          -  Administration of immunoglobulins and/or any blood products within 3 months, or
             administration of any live attenuated vaccine within 28 days, or administration of any
             subunit or inactivated vaccines within 14 days.

          -  Fever or axillary temperature&gt; 37.0 Â°C before vaccination

          -  During menstrual period, breastfeeding, pregnancy(pregnancy test positive), or planned
             pregnant within 7 month

          -  History of hypertension, physical examination systolic blood pressure&gt; 150mmHg and/or
             diastolic blood pressure&gt; 100mmHg

          -  Abnormal laboratory tests parameters

          -  Any clinical significant disease or findings during study screening that, in the
             opinion of the Investigator may interfere with the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yan-ping Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangxi Centers for Disease Control and Prevention</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GuangXi Center for Diseases Control and Prevention</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 5, 2012</last_update_submitted>
  <last_update_submitted_qc>March 5, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Human papillomavirus</keyword>
  <keyword>vaccine</keyword>
  <keyword>cervical infection</keyword>
  <keyword>cervical cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Aluminum phosphate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 13, 2016</submitted>
    <returned>May 18, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

